Hydergine

Hydergine (Ergoloid Mesylates)

Hydergine (Ergoloid Mesylates) belongs to the family of medicines known as ergot alkaloid, which are group of compounds produced by fungi in the genus Claviceps. This brain booster is consists of methanesulfonate salts from three dihydrogenated ergot alkaloids. As a pharmaceutical drug, is used to treat mood or behavioral disorders, problems caused by Alzheimer’s disease, age-related cognitive impairments, and stroke.

Overall Health Benefits of Hydergine (Ergoloid Mesylates)

• Improves Cognitive Function and Brain Health [3-16]
• Improves Symptoms of Stroke [103-107]
• Treats Tardive Dyskinesia [108-111]
• Wards Off Depression and Anxiety [112-125]
• Fights Fatigue [126-127]
• Treats Hearing Loss [128]
• Reduces Vertigo [129-130]
• Promotes Restful Sleep [131-133]
• Treats Headaches and Body Pains [134-141]
• Lowers Blood Pressure [142-143]

How does Hydergine Works?

Hydergine exerts its brain-boosting effects by increasing the levels of the neurotransmitters (brain chemicals) dopamine and serotonin – both of which plays an integral role in the maintenance of cognitive function. [1-2] In addition, another important mechanism by which hydergine improves cognitive health is by boosting blood flow within the brain.

Proven Health Benefits of Hydergine

The components of hydergine are derived from potent neurochemicals and have undergone decades of testing and research. The following are among the proven health benefits of hydergine:

Improves Cognitive Function and Brain Health

Strong scientific evidence suggests that hydergine can help improve various aspects of cognitive function such as memory and thinking skills:

1. In patients with possible Alzheimer’s dementia, supplementation with daily doses of hydergine at 4 mg or more improved neuropsychological measures compared to placebo.[3-16]
2. In elderly patients with age-related mental deterioration, administration of hydergine at 4.5 mg per day for 6 months resulted in a significant reduction in cognitive deficits, anxiety, mood depression, unsociability, and irritability. [17-19]
3. In an analysis of multiple studies assessing the benefits of hydergine, researchers found that hydergine has positive effects on different aspects of cognitive function. [20]
4. In healthy elderly volunteers, hydergine administration improved performances on tests of intelligence. [21-22]
5. Studies show that hydergine improves brain health by enhancing the metabolism of cerebral ganglionic cells (brain cells), increasing the uptake of water, blood sugar and oxygen in cerebral cells, and stimulating dilation of blood vessels to improve blood circulation within the brain. [23-24]
6. In patients with clinically significant evidence of mental aging, administration of hydergine at a dose of 3 mg per day significantly improved the severity of symptoms and intellectual function. [25-26]
7. In patients with mild-to-moderate mental deterioration, hydergine supplementation significantly improved cognition and functioning. [27-29]
8. Administration of a different formulation of hydergine as a liquid in a capsule in patients with cognitive impairment led to a significant improvement in symptoms. [30]
9. In patients with chronic senile cerebral insufficiency, a rare condition characterized by obstruction of one or more arteries that supply blood to the brain, hydergine supplementation at a dose of 1.5 mg thrice a day for 6-12 months improved the severity of symptoms. [31-33]
10. In patients with late life organic brain syndromes, a group of conditions that frequently leads to impaired cognitive function, hydergine administration resulted in improvement in mental function and symptom rating scale. [34-40]
11. In elderly patients with cerebrovascular insufficiency, hydergine administration resulted in statistically significant improvement in symptoms with no evident side effects.[41-58]
12. In patients with symptoms of primary degenerative dementia, hydergine administration at a dose of 6 mg/day improved attention and other behavioral parameters. [59-63]
13. In elderly patients with cognitive impairment, hydergine had a statistically significant effect on cognitive status. [64]
14. In patients with organic brain syndrome and cerebral arteriosclerosis, hydergine administration for 12 weeks is associated with greater symptomatic relief compared to placebo. [65-67]
15. In subjects with senile mental deterioration, hydergine administration for 24 weeks improved qualitative aspects of performance such as attention and concentration. [68-73]
16. In patients with dementia, hydergine consistently produced statistically significant improvement in 13 symptoms associated with the condition. [74-79]
17. In patients affected by multi-infarct dementia, daily intravenous infusion of 3 mg hydergine over 14 days had a fast and clinically relevant effect on the key clinical symptoms of the disease. [80-81]
18. In patients with chronic psychosis, a severe mental disorder characterized by impaired emotions and detachment from reality, hydergine treatment improved psychotic symptoms. [82-83]
19. In geriatric patients with cerebrovascular disorders, administration of sublingual tablets of hydergine for twelve weeks improved cognition and intellectual function without untoward effects. [84-88]
20. In healthy elderly men and women, hydergine administration is associated with significant improvement in physical and mental health. [89-90]
21. In patients with Alzheimer’s disease, combination therapy with lecithin and ergoloid mesylates improved the abilities of patients to detect spatial arrangements, recognize faces, and identify new words. [90-91]
22. In elderly patients with signs of cerebrovascular impairment, administration of hydergine at 4.5 mg daily is associated with significant improvement in mental activity and increased blood circulation in the brain. [93-94]
23. A study assessing 26 clinical drug trials showed that hydergine treatment is effective at improving age-related cognitive dysfunction. [95]
24. In patients aged 55 to 80 years with mild memory impairment, hydergine administration at 6 mg per day for 12 weeks enhanced short-term memory function. [96]
25. In patients with cognitive impairment, hydergine administration improves various areas of cognitive functions as evidenced by improved electroencephalogram findings. [97-98]
26. Studies show that hydergine is in par with Alzheimer’s drugs such as levodopa with regards to improving cognitive function related to this disease. [99]
27. In healthy elderly men and women, hydergine treatment is associated with improved performances on tests of intelligence. [100]
28. In patients with hardened brain arteries, hydergine administration improved a number of physical and psychological symptoms such as confusion, dizziness, orientation, fatigue, emotional stability, motivation, short-term memory, depression, anxiety, cooperation, sociability, self-care, and locomotion. [101]
29. In patients with low oxygen levels (hypoxia), hydergine reduced brain dysfunction by improving brain electrical activity. [102]

Improves Symptoms of Stroke

A stroke is a life-threatening situation. This medical condition occurs when blood flow going to your brain is cut off, resulting in death of brain cells. Interestingly, hydergine has the ability to boost blood circulation in the brain. Studies show that this key mechanism can help accelerate recovery in stroke patients:

1. In patients who had subarachnoid hemorrhage, intravenous hydergine administration significantly reduced stroke symptoms. [103]
2. In elderly female patients (74 to 79 years of age) with multi-infarct dementia, hydergine injection increased brain glucose use, which is suggestive of improved brain cell activity. [104]
3. In stroke patients, oral or intramuscular dose of hydergine improved limb function, mental deterioration, and electrical activity of the brain. [105]
4. In an animal model of stroke, hydergine markedly reduced neuronal death following 5 minutes of restricted blood supply in the brain. [106]
5. In rats subjected to multiple brain infarctions, hydergine reduced swelling and improved brain blood flow. [107]

Treats Tardive Dyskinesia

Tardive dyskinesia (TD) is a disorder characterized by uncontrollable, repetitive body movements. This may include blinking, grimacing, lip smacking, or sticking out the tongue. There is h3 scientific evidence that hydergine can help treat this debilitating medical condition:

1. In patients with tardive dyskinesia, hydergine administration reduced repetitive body movements. [108]
2. In patients with abnormal involuntary movements of tardive dyskinesia, hydergine treatment at a dose of 3 to 4 milligrams a day for six weeks significantly reduced symptoms. [109]
3. In elderly chronic psychiatric patients, hydergine is associated with a reduction of dyskinetic scores compared to placebo. [110]
4. In patients with signs of tardive dyskinesia secondary to antipsychotic medication, hydergine administration at a dose of 4.5 mg once daily for 6 weeks reduced dyskinetic scores. [111]

Wards Off Depression and Anxiety

The brain-boosting properties of hydergine do not only improve cognitive function. Several lines of evidence support its antidepressant and anti-anxiety effect:

1. In patients with depression and dementia, hydergine administration improved depressive symptoms without adverse side effects. [112]
2. In elderly patients with age-related mental deterioration, 4.5 mg daily dose of hydergine for 6 months improved depressive symptoms such as unsociability and irritability. [113]
3. In aged patients with hardened brain arteries, hydergine administration improved motivation, cooperation, sociability, self-care, fatigue, and locomotion. [114]
4. In patients with dementia, hydergine improved depressive mood. [115]
5. In nursing home residents with organic brain syndrome, hydergine administration decreased symptoms of depression. [116]
6. In elderly nursing home patients, hydergine treatment for 12 weeks improved motivation. [117]
7. In patients with possible Alzheimer’s dementia, supplementation with daily doses of hydergine at 4 mg or more improved neuropsychological measures of depression. [118]
8. A review of 26 clinical studies found that hydergine administration at varying doses had a positive effect on mood. [119]
9. In elderly patients with age-related mental deterioration, administration of hydergine at 4.5 mg per day for 6 months resulted in a significant reduction in anxiety, mood depression, unsociability, and irritability. [120]
10. In patients receiving electroconvulsive therapy, hydergine treatment is associated with significantly better antidepressant response. [121]
11. In patients with alcohol-related encephalopathy, a condition that refers to brain disease, damage, or malfunction, hydergine treatment improved symptoms of depression such as sleep disturbance and agitation. [122]
12. Results from twelve different clinical trials conducted in patients with dementia showed that hydergine significantly decreased anxiety. [123]
13. In elderly patients with mental deterioration, hydergine administration at a dose of 4.5 mg for 6 months significantly reduced mood depression and anxiety. [124]
14. In 16 elderly patients, hydergine administration for 3 months decreased anxiety and irritability. [125]

Fights Fatigue

Hydergine also has a potent anti-fatigue effect that can help boost energy levels. Studies show that this powerful ergot alkaloid can help combat fatigue induced by aging and other debilitating medical conditions:

1. In aged individuals with reduced blood flow to the brain, hydergine administration reduced symptoms of fatigue. [126]
2. A study reviewing 12 trials assessing the benefits of hydergine in dementia patients showed that the treatment significantly reduced fatigue. [127]

Treats Hearing Loss

Aging leads to hearing loss and significantly impairs one’s ability to communicate. This is because the aging process may cause changes in the inner ear structures, blood flow to the ear, and in the way your brain interprets speech and sound.

In a study of 17 patients with age-related problems of the inner ear, the researchers concluded that hydergine drops may help improve hearing by 20%. [128] All patients were treated only with hydergine at a dose of 30 drops (4.5 mg) thrice daily. Results of the study showed a 57% reduction in ringing in the ears (tinnitus) and a 20% reduction in impaired response to normal noises.

Reduces Vertigo

Vertigo is an unpleasant symptom and is characterized by a feeling that your surrounding is spinning. While some types of vertigo resolve without treatment, this condition can be a sign of an underlying medical problem of the brain or inner ear. For people with acute or chronic vertigo, studies show that hydergine exerts beneficial effects:

1. In aged patients with decreased brain blood flow, hydergine administration reduced the occurrence of vertigo. [129]
2. In patients with hearing loss, hydergine treatment improved symptoms of vertigo. [130]

Promotes Restful Sleep

Sleeping problems are very common in people with advancing age. The good news is that hydergine can help improve sleep quality and quantity in the elderly according to high quality studies:

1. In aged patients with reduced blood flow in the brain, hydergine administration decreased symptoms of sleep disorders. [131]
2. In patients with alcohol-related encephalopathy, oral hydergine administration reduced sleep disturbance and agitation. [132]
3. In rats, hydergine injections reversed sleep disturbance induced by low oxygen levels. [133]

Treats Headaches and Body Pains

Hydergine is not only a powerful cognitive enhancer. There is increasing evidence that hydergine has potent pain-relieving properties:

1. In patients who experienced migraines, hydergine use significantly reduced the frequency of headache attacks, days with a headache, and consumption of painkillers. [134]
2. In patients with migraines and cluster headaches, administration of sublingual hydergine tablets at a dose of 0.5 mg reduced symptoms by increasing blood flow to the brain. [135]
3. One study found that hydergine and other ergot alkaloids are in par with pain relievers for the treatment of headaches. [136]
4. In patients with headaches secondary to vascular deficiency, hydergine treatment relieved symptoms. [137]
5. Hydergine administration in patients with vasomotor headache, a type of headache that occurs during abrupt position changes, reduced the frequency and intensity of headaches. [138]
6. In patients with pain associated with sickle cell crisis, hydergine administration reduced pain intensity without adverse side effects. [139]
7. Hydergine administration also reduced pain in patients with painful posttraumatic osteoporosis. [140]
8. Hydergine was also effective in the treatment of patients with painful shoulder and shoulder-band syndrome. [141]

Lowers Blood Pressure

Ergot alkaloids also possess anti-hypertensive properties. Studies show that ergot alkaloids can help reduce blood pressure to normal limits without any adverse side effects:

1. In patients aged 25 to 56 years, oral and intravenous administration of the dihydrogenated ergot alkaloids significantly reduced blood pressure without side effects. [142]
2. In patients with arterial hypertension, hydergine reduced blood pressure by dilating blood vessels. [143]

References:

1. Markstein R. Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17.
2. Theinhaus OJ, Wheeler BG, Simon S, et al. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc. 1987;35:219-223.
3. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol. 1994;51(8):787-98.
4. Cox JR. Selected patients treated with Hydergine ‐ a double‐blind trial. Brit. J. Clin. Pract 1982;16:9‐11.
5. Cox JR, Pandurangi VR, Wallace, MG. Drugs will help if dementing patients are caught early. Modern Geriatrics 1978;8(12):14‐15.
6. Exton‐Smith AN, Piper M, Phillips M, Simpson J. Clinical experience with ergot alkaloids. Clinical experience with ergot alkaloids 1983;23:323‐328.
7. Exton‐Smith AN, Piper ME, Phillips MJ, Simpson, JM. Management of elderly patients with dementia: A clinical trial using high doses of Hydergine. British Journal of Clinical Practice 1982;16:55‐58.
8. Hydergine helpful for Alzheimer’s disease. Geriatrics. 1979;34(10):23.
9. Desimirovic V, Vujic D, Vlajkovic J. Comparative longterm study of dihydroergotoxine and cinarizine effects on incipient dementia syndrome. Therapie 1988;43:143‐63.
10. Jenike MA, Albert M, Baer L, Gunther J, et al. Ergot mesylates for Alzheimer’s disease: A year‐long double‐blind trial of 3mg vs 12 mg daily. International Journal of Geriatric Psychiatry 1990;5(6):375‐380.
11. McDonald S, Patin J. A double‐blind, placebo‐controlled study of the safety and efficacy of 4.5mg and 9.0 mg/day of Hydergine FAS capsules in patients with Alzheimer’s disease. Unpublished manuscript , submitted by Sandoz Research Institute, East Hanover, NJ1989.ro
12. Tecce JJ, Boehner MB, Cattanach L, Branconnier R, Cole JO. Hydergine treatment and brain‐functioning (CNV rebound) in Alzheimer’s patients: preliminary findings. Psychoparmacology Bulletin 1981;17:202‐6.
13. Tecce JJ, Cattanach L, Boehner-davis MB, Branconnier RJ, Cole JO. [Neuropsychological study of decline of attention and drug therapy of patients with Alzheimer’s disease]. Presse Med. 1983;12(48):3155-62.
14. Tecce JJ, Cattanach L, Boehner-davis MB, Branconnier RJ, Cole JO. [Neuropsychological study of decline of attention and drug therapy of patients with Alzheimer’s disease]. Presse Med. 1983;12(48):3155-62.
15. Tecce JJ, Cattanach L, Boehner‐Davis MB, Branconnier RJ, Cole JO. CNV rebound, attention performance, and Hydergine treatment in Alzheimer patients. British Journal of Clinical Practice. Symposium Supplement 1983;30:19‐22.
16. Tinklenberg JR, Davies HD, Miller TP, Moylan AE. High dose hydergine treatment of alzheimer’s patients: Final report. Unpublished manuscript1993.
17. Rouy JM, Douillon AM, Compan B, Wolmark Y. Ergoloid mesylates (‘Hydergine’) in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11(6):380-9.
18. Bargheon J. Double‐blind study of Hydergine in elderly patients. La Nouvelle Presse Medicale 1973;2:2053‐5.
19. Puxty J. High‐dose Ergoloid Mesylates (Hydergine) in community residing patients with age‐related mental decline. 7th submission to the Journal of the American Geriatric Association1991.
20. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev. 2000;(2):CD000359.
21. Spiegel R, Huber F, Köberle S. A controlled long-term study with ergoloid mesylates (Hydergine) in healthy, elderly volunteers: results after three years. J Am Geriatr Soc. 1983;31(9):549-55.
22. Köberle S, Spiegel R. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years. Gerontology. 1984;30 Suppl 1:3-52.
23. Burian E. An ergot alkaloid preparation (hydergine) in the treatment of presenile brain atrophy (Alzheimer’s disease): case report. J Am Geriatr Soc. 1974;22:126-128.
24. Yesavage JA, Hollister LE, Burian E. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report. J Am Geriatr Soc. 1979;27:80-82.
25. Rosen HJ. Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine). J Am Geriatr Soc. 1975;23:169-174.
26. Bazo AJ. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double‐blind study. Journal of the American Geriatrics Society 1973;21:63‐71.
27. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333-1341.
28. Battaglia Angelo, Bruni G, Sacchetti G, Pamparana F, et al. A double‐blind randomized study of two ergot derivatives in mild to moderate dementia.. Current Therapeutic Research 1990;48(4):597‐612.
29. Thienhaus OJ, Wheeler BG, Simon S, Zemlan FP, Hartford JT. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc. 1987;35(3):219-23.
30. Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Datab System Rev. 2004;2.
31. Retrieved from https://www.researchgate.net/publication/302355015_Implications_of_Long-Term_Study_of_Hydergine_in_Elderly_Patients_with_Chronic_Senile_Cerebral_Insufficiency.
32. Arrigo, A. Influence of Hydergine on senile cerebrovascular disorders and its correlation with changes in the electroencephalogram. Investigacion Medica Internacional 1975;45:45‐60.
33. Grill P, Broicher B. Therapy for cerebral insufficiency. Dtsch. Med. Wschr. 1969;94:2429‐35.
34. Gaitz CM, Varner RV. Pharmacoptherapy of late life organic brain syndromes: evaluation of hydergine (an ergot derivative) versus placebo using double blind technique. Gerontologist 1974;14(5(II)):44.
35. Gaitz CM, Varner RV, Overall JE. Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry. 1977;34(7):839-45.
36. Biel ML, Seus R, Struppler A. [Treatment of organic brain psychosyndrom in the old age. A double blind study with Hydergin (author’s transl)]. Med Klin. 1976;71(49):2177-84.
37. Jarvik LF. Hydergine as a treatment for organic brain syndrome in late life. Psychopharmocology 1981;36:3680‐2.
38. Saletu B, Grünberger J, Anderer R. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol. 1990;28(12):510-24.
39. Thibault A. A double-blind evaluation of ‘Hydergine’ and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin. 1974;2(8):482-7.
40. Klebel E, Hutter M, Maritsch F. The influence of co‐derogocrine mesilate (hydergine FAS) on psychometric performance of elderly patients with organic brain syndrome. Zeitschrift Fur Gerontolgie and Psychiatrie 1992;5(1):43‐55.
41. Mcconnachie RW. A clinical trial comparing ‘Hydergine’ with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin. 1973;1(8):463-8.
42. Dihydrogenated ergot alkaloids (Hydergine) and cerebrovascular insufficiency. Med Lett Drugs Ther. 1970;12(6):27-8.
43. Arrigo A, Kauchtschischwili GM, Tartara A. EEG and clinical effects of Hydergine in cerebral vascular insufficiency. 9th International Congress of Gerontology. 1972; Vol. 3:68.
44. Atarashi J, Ohtomo E, Kogure K, Hirai S, Tazaki Y, Araki G, Itoh E, Sawada T, Fujishima M. Clinical utility of HYG‐FAS in treatment of cerebrovascular disorders: Multi‐center double‐blind study in comparison with Hydergine tablet 2mg. Rinsho Hyoka (Clin. Eval) 1988;16:425‐486.
45. Banen DM. An ergot preparation (Hydergine) for relief of symptoms of cerebrovascular insufficiency. J Am Geriatr Soc. 1972;20(1):22-4.
46. Dennler HJ, Bachmann H. [Hydergin therapy of cerebrovascular insufficiency in patients requiring digitalis. Results of a double-blind study (author’s transl)]. MMW Munch Med Wochenschr. 1979;121(48):1615-8.
47. Gerin J. Symptomatic treatment of cerebrovascular insufficiency with Hydergine. Current Therapeutic Research 1969;1:539‐46.
48. Herzfeld U, Christian W, Oswald WD, Ronge J, Wittgen M. [Analysis of the effect of Hydergin in long-term trial. An interdisciplinary study]. Med Klin. 1972;67(35):1118-25.
49. Jansen W, Bruckner GW, Jansen P. The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids. J Int Med Res. 1985;13(1):48-53.
50. Jennings WG. An ergot alkaloid preparation (hydergine) versus placebo for treatment of symptoms of cerebrovascular insufficiency: double-blind study. J Am Geriatr Soc. 1972;20(8):407-12.
51. Misra SC, Patnaik BC, Patnaik SR, Panda RK, Maharana SN. Dehydroergotoxine mesylate (Hydergine) in cerebrovascular insufficiency (Summary). J. Assoc. Physicians India 1982;30:696.
52. Mcdonald RJ. Hydergine: a review of 26 clinical studies. Pharmakopsychiatr Neuropsychopharmakol. 1979;12(6):407-22.
53. Moglia A, Bono G, Sinforiani E, et al. [Dihydroergotoxine mesylate in chronic cerebrovascular insufficiency: spectral EEG analysis and neuropsychological correlates]. Farmaco Prat. 1983;38(2):97-102.
54. Rao DB, Norris JR. A double-blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopkins Med J. 1972;130(5):317-24.
55. Rehman SA. Two trials comparing ‘Hydergine’ with placebo in the treatment of patients suffering from cerebrovascular insufficiency. Curr Med Res Opin. 1973;1(8):456-62.
56. Tartara A, Kauchtschischvili G, Arrigo A, Moglia A. EEG and clinical effects of diidroergotoxinemethansulphonate in cerebrovascular insufficiency. G. Geront. 1974;22:298‐309.
57. Teixeira JE. [Hydergine in the symptomatic treatment of cerebrovascular insufficiency. Comparative clinical test with a placebo]. Hospital (Rio J). 1970;77(6):1907-31.
58. Triboletti F, Ferri H. Hydergine for treatment of symptoms of cerebrovascular insufficiency. Curr Ther Res Clin Exp. 1969;11(10):609-20.
59. McDonald RJ. A double‐blind, placebo‐controlled study of the effect of 6 mg/day Hydergine on attention and other behavioral parameters in outpatients with symptoms of primary degenerative dementia. Unpublished manuscript No. 66, submitted by Sandoz Pharmaceuticals Inc, East Hanover, NJ1985.
60. McDonald RJ. A double‐blind, placebo‐controlled study of the effect of 6 mg/day Hydergine on attention and other behavioral parameters in outpatients with symptoms of primary degenerative dementia. Unpublished manuscript No. 65, submitted by Sandoz Pharmaceuticals Inc, East Hanover, NJ1985.
61. Kuskowski MA, Morley G, Malone SM, Dysken MW, Okaya A. Hydergine treatment and psychophysiological measures in primary degenerative dementia. Journal of Psychiatry and Neurology 1990;3:41‐7.
62. Liu XD, Wan Q, Wei D, Wang XM. Cognitive and non‐cognitive functions in patients with vascular dementia and the interventional efficacy of dihydroergotamine mesilate plus nimodipine. Chinese Journal of Clinical Rehabilitation 2005;9(20):48‐9.
63. Patin J, Hamot HB. A double‐blind placebo‐controlled, multi‐clinic study to evaluate the safety and efficacy of a total daily dose of 6.0 mg of Hydergine for the treatment of cognitive, affective and behavioral symptoms associated with aging. Unpublished manuscript: Statistical report for Sandoz Pharmaceutical Research and Development1981.
64. Retrieved from https://link.springer.com/article/10.1007/BF02434076.
65. Thibault A. A double-blind evaluation of ‘Hydergine’ and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin. 1974;2(8):482-7.
66. Labecki TD, Busby CL. Dihydrogenated ergot derivatives in cerebral arteriosclerosis. Journal of Gerontology 1954;9:485.
67. Lozeron H. [Hydergine in the treatment of cerebral circulatory disorders, including arteriosclerosis (author’s transl)]. Schweiz Rundsch Med Prax. 1974;63(21):660-5.
68. Van loveren-huyben CM, Engelaar HF, Hermans MB, Van der bom JA, Leering C, Munnichs JM. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc. 1984;32(8):584-8.
69. Hofstatter L, Ossorio A, Mandl B, Kohler LH, Busch AK, Hyman A. Pharmaceutical treatment of patients with senile brain changes. AMA Arch Neurol Psychiatry. 1956;75(3):316-22.
70. Irfan S, Linder L. The effect of dihydrogenated ergot alkaloids in the treatment of geriatric patients suffering from senile mental deterioration. XI International Congress of Gerontolgy. Tokyo, Japan: SCIMED Publishers, Inc., 1978:142.
71. Linder L, Irfan S. Hydergine in the treatment of geriatric patients suffering from senile mental deterioration. VIth World Congress of Psychiatry, Honolulu, HI. Washington, DC: American Psychiatric Association., 1977; Vol. 1025:188.
72. Matejcek M, Knor K, Piguet PV, Weil C. Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation. J Am Geriatr Soc. 1979;27(5):198-202.
73. Yesavage JA, Hollister LE, Burian E. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report. J Am Geriatr Soc. 1979;27(2):80-2.
74. Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc. 1976;24(11):490-7.
75. Breeze RW, Cox S, Rodgers‐Cox J. Changes in P‐300 latency as a result of co‐dergocrine mesylate therapy in patients with senile dementia. International Journal of Geriatric Psychiatry 1988;3:263‐6.
76. Popkin RJ. The hydrogenated alkaloids of ergot (hydergine) in geriatrics; follow-up study. Am Pract Dig Treat. 1956;7(10):1594-7.
77. Spilich GJ, Wannenmacher W, Duarte A, Buendia R, Gomez JT, Ramirez S, Anaya A, Otero E. Effiacy of pyritinol versus hydergine upon cognitive performance in patients with senile dementia of the Alzheimer’s type: A double‐blind multi‐center trial. Alzheimer’s Research 1996;2(3):79‐84.
78. Tucker JS. An assessment of the effect of intramuscular Hydergine in elderly patients with early dementia using critical flicker fusion thresholds. British Journal of Clinical Practice 1982;16:16‐17.
79. Yesavage JA, Westphal J, Rush L. Senile dementia: combined pharmacologic and psychologic treatment. J Am Geriatr Soc. 1981;29(4):164-71.
80. Arrigo A, Casale R, Giorgi I, Guarnaschelli C, Zelaschi F. Effects of intravenous high dose co-dergocrine mesylate (‘Hydergine’) in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11(8):491-500.
81. Casale R, Buonocore M, Arrigo A. Role of i.v. administration of Hydergine in the initial stage of treatment of multi‐infarct dementia: Influence on the psychomotor performances and the shortening of the effects’ onset period. In: Carlsson A, Kanowski S, Allain H, Spiegel R editor(s). Cerebral Insufficiency: Trends in Research and Treatment. Vol. 4, Carnforth, Lancs, UK/Park Ridge, NJ: The Parthenon Publishing Group, 1989:193‐209.
82. Bohard F, Guennoc A, Klein H, Le borgne Y, Masanes P. [Hydergine in the treatment of chronic psychoses]. Ann Med Psychol (Paris). 1967;125(3):438-46.
83. Forster W, Schultz S, Henderson AL. Combined hydrogenated alkaloids of ergot in senile and arteriosclerotic psychoses. Geriatrics. 1955;10(1):26-30.
84. Ditch M, Kelly FJ, Resnick O. An ergot preparation (hydergine) in the treatment of cerebrovascular disorders in the geriatric patient: double-blind study. J Am Geriatr Soc. 1971;19(3):208-17.
85. Hollingsworth SW. Response of geriatric patients from the satellite nursing homes of Maricopa County to Hydergine therapy: A double‐blind study. Current Therapeutic Research 1980;27:401‐10.
86. Rehman SA. Two trials comparing ‘Hydergine’ with placebo in the treatment of patients suffering from cerebrovascular insufficiency. Curr Med Res Opin. 1973;1(8):456-62.Roubicek J, Geiger CH, Abt K. An ergot alkaloid preparation (Hydergine) in geriatric therapy. Journal of the American Geriatrics Society 1972;5:222‐9.
87. Roubicek J, Geiger CH, Abt K, Huber F. Hydergine therapy in geriatric patients. In: Steinmann B, Huber H editor(s). Proceedings of the VI European Congress of Clinical Gerontology. Berne, Switzerland: Verlag, 1973:468‐81.
88. Yoshikawa M, Hirai S, Aizawa T, et al. A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances. J Am Geriatr Soc. 1983;31(1):1-7.
89. Huber F, Köberle S, Prestele H, Spiegel R. Effects of long-term ergoloid mesylates (‘Hydergine’) administration in healthy pensioners: 5-year results. Curr Med Res Opin. 1986;10(4):256-79.
90. Paux G, Boismare F, Delaunay P. [Letter: Double blind study of hydergine in aged patients]. Nouv Presse Med. 1975;4(35):2529.
91. Jenike MA, Albert MS, Heller H, Locastro S, Gunther J. Combination therapy with lecithin and ergoloid mesylates for Alzheimer’s disease. J Clin Psychiatry. 1986;47(5):249-51.
92. Pomara N, Block R, Abraham J, Domino EF, Gershon S. Combined cholinergic precursor treatment and dihydroergotoxine mesylate in Alzheimer’s disease. IRCS Med. Sci: Psychology and Psychiatry 1983;11:1048‐9.
93. Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D. [Long-term treatment of cerebrovascular changes in the elderly (author’s transl)]. Dtsch Med Wochenschr. 1978;103(11):456-62.
94. Novo FP, Ryan RP, Frazier, EL. Dihydroergotoxine Mesylate in the treatment of symptoms of idiopathic cerebral dysfunction in geriatric patients. Clin. Ther. 1978;1:359‐69.
95. Mcdonald RJ. Hydergine: a review of 26 clinical studies. Pharmakopsychiatr Neuropsychopharmakol. 1979;12(6):407-22.
96. Thienhaus OJ, Wheeler BG, Simon S, Zemlan FP, Hartford JT. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc. 1987;35(3):219-23.
97. Pires de oliveira RS. [Electroencephalographic alterations after administration of vaso-active substance (Hydergine)]. Arq Neuropsiquiatr. 1973;31(2):107-22.
98. Saletu B, Grünberger J, Anderer P, Linzmayer L, Pakesch G, Zyhlarz G. Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard and Hydergine) by EEG mapping and psychometry under hypoxia. Arch Gerontol Geriatr. 1994;18(2):81-99.
99. Shoptaw S, Watson DW, Reiber C, Rawson RA, Montgomery MA, Majewska MD, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005;100(Suppl):178‐90.
100. Spiegel R, Huber F, Köberle S. A controlled long-term study with ergoloid mesylates (Hydergine) in healthy, elderly volunteers: results after three years. J Am Geriatr Soc. 1983;31(9):549-55.
101. Bargheon J. [Double blind test of hydergine in the aged]. Nouv Presse Med. 1973;2(31):2053-5.
102. Saletu B, Grünberger J, Anderer R. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol. 1990;28(12):510-24.
103. Cook PJ, Burgoyne W, James IM. Effect of intravenous Hydergine on cerebral blood flow in patients following subarachnoid haemorrhage. British Journal of Clinical Practice 1982;16:32‐4.
104. Nagasawa H, Kogure K, Kawashima K, Ido T, Itoh M, Hatazawa J. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography. Tohoku J Exp Med. 1990;162(3):225-33.
105. Elwan O, Helmy AA, Tamawy ME, et al. Ergoloids and ischaemic strokes; efficacy and mechanism of action. J Int Med Res. 1995;23(3):154-66.
106. Izumiyama K, Kogure K. Effect of dihydroergotoxine mesylate (Hydergine) on delayed neuronal death in the gerbil hippocampus. Acta Neurol Scand. 1988;78(3):214-20.
107. Kristián T, Siesjö BK. Calcium in ischemic cell death. Stroke. 1998;29(3):705-18.
108. Chien C, Marder SR, Putten T, Escobar J. A double‐blind study of dihydrogenated ergot alkaloids (Hydergine) in the treatment of tardive dyskinesia: preliminary report. 12th Congress of the Collegium Internationale Neuro‐Pharmacologicum, Goteborg (S), 22‐26 June. Oxford, New York: Pergamon Press, 1980; Vol. 120:105‐106.
109. Mohamed SN, Kazarian S, Merskey H, Thompson MG. Treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (hydergine): a pilot study. Can J Psychiatry. 1980;25(4):325-8.
110. Rastogi SC, Blowers AJ, Gibson AC. Co-dergocrine (hydergine) in the treatment of tardive dyskinesia. Psychol Med. 1982;12(2):427-9.
111. Hajioff J, Wallace M. Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report. Psychopharmacology (Berl). 1983;79(1):1-3.
112. Good WR, Griffiths RA. Hydergine in depression and dementia.. British Journal of Clinical Practice 1982;16:38‐42.
113. Rouy JM, Douillon AM, Compan B, Wolmark Y. Ergoloid mesylates (‘Hydergine’) in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11(6):380-9.
114. Bargheon J. [Double blind test of hydergine in the aged]. Nouv Presse Med. 1973;2(31):2053-5.
115. Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc. 1976;24(11):490-7.
116. Gaitz CM, Varner RV, Overall JE. Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry. 1977;34(7):839-45.
117. Bazo AJ. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study. J Am Geriatr Soc. 1973;21(2):63-71.
118. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol. 1994;51(8):787-98.
119. Mcdonald RJ. Hydergine: a review of 26 clinical studies. Pharmakopsychiatr Neuropsychopharmakol. 1979;12(6):407-22.
120. Rouy JM, Douillon AM, Compan B, Wolmark Y. Ergoloid mesylates (‘Hydergine’) in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11(6):380-9.
121. Sachs GS, Gelenberg AJ, Bellinghausen B, et al. Ergoloid mesylates and ECT. J Clin Psychiatry. 1989;50(3):87-90.
122. Datta KD, Evenson RC, Gannon PJ, Dick EP. Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(1):87-90.
123. Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc. 1976;24(11):490-7.
124. Rouy JM, Douillon AM, Compan B, Wolmark Y. Ergoloid mesylates (‘Hydergine’) in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11(6):380-9.
125. Matejcek M, Knor K, Piguet PV, Weil C. Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation. J Am Geriatr Soc. 1979;27(5):198-202.
126. Mcconnachie RW. A clinical trial comparing ‘Hydergine’ with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin. 1973;1(8):463-8.
127. Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc. 1976;24(11):490-7.
128. Jiménez-cervantes nicolás J, Amorós rodríguez LM. [Hydergine in pathology of the inner ear]. An Otorrinolaringol Ibero Am. 1990;17(1):85-98.
129. Arrigo A, Braun P, Kauchtschischwili GM, Moglia A, Tartara A. Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged. Curr Ther Res Clin Exp. 1973;15(7):417-26.
130. Jiménez-cervantes nicolás J, Amorós rodríguez LM. [Hydergine in pathology of the inner ear]. An Otorrinolaringol Ibero Am. 1990;17(1):85-98.
131. Arrigo A, Braun P, Kauchtschischwili GM, Moglia A, Tartara A. Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged. Curr Ther Res Clin Exp. 1973;15(7):417-26.
132. Datta KD, Evenson RC, Gannon PJ, Dick EP. Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(1):87-90.
133. Laszy J, Sarkadi A. Hypoxia-induced sleep disturbance in rats. Sleep. 1990;13(3):205-17.
134. Micieli G, Cavallini A, Marcheselli S, Mailland F, Ambrosoli L, Nappi G. Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. Int J Clin Pharmacol Ther. 2001;39(4):144-51.
135. Yamamoto M, Meyer JS. Hemicranial disorder of vasomotor adrenoceptors in migraine and cluster headache. Headache. 1980;20(6):321-35.
136. Von albert HH, Marguth F. [Therapy of headaches, including migraine]. Bibl Psychiatr Neurol. 1969;139:152-8.
137. Henry P. [Headaches in patients with vascular deficiency and their treatment with a raubasine-dihydroergocristine association]. Bord Med. 1972;5(18):2531-4.
138. Niesel P, Weigelin E, Ossendorf I. [Hydergine and DHE 45 therapy of vasomotor headache]. Schweiz Med Wochenschr. 1953;83(22):518-23.
139. Ducloux M, Cuisinier JC, Barbotin M, Lagarde B, Plassart H. [Treatment of painful drepanocytic crises with Hydergine]. Bull Soc Med Afr Noire Lang Fr. 1973;18(1):105-9.
140. David-chausse J, David-chausse F, Cormier M. [Treatment of painful posttraumatic osteoporosis with hydergine]. J Med Bord. 1957;134(6):837-47.
141. Yaya Huamán R, Blasco Olcina R, García Fernández M, Vilches Padilla JJ. [A study of 93 cases of painful shoulder and shoulder-band syndrome treated with hydergine (author’s transl)]. Rev Esp Otoneurooftalmol Neurocir. 1975 May-Jun;33(193):131-5. Spanish. PubMed PMID: 56021.
142. Dupuy HJ, Signorelli J, Attyah AM. Dihydrogenated ergot alkaloids in the treatment of essential hypertension. Circulation. 1952;5(2):285-6.
143. Tandowsky RM. Clinical evaluation of combined hydrogenated ergot alkaloids (hydergine) in arterial hypertension with special reference to their action in central manifestations. Circulation. 1954;9(1):48-56.